First Time Loading...

Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 6.29 USD 1.94% Market Closed
Updated: May 21, 2024

Operating Margin
Ocular Therapeutix Inc

-152.8%
Current
-173%
Average
7.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-152.8%
=
Operating Profit
-91.4m
/
Revenue
59.8m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Ocular Therapeutix Inc
NASDAQ:OCUL
973.1m USD
-153%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
744.3B USD
32%
DK
Novo Nordisk A/S
CSE:NOVO B
4.1T DKK
45%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
364.1B USD
28%
US
Merck & Co Inc
NYSE:MRK
331.8B USD
10%
UK
AstraZeneca PLC
LSE:AZN
189.2B GBP
18%
CH
Roche Holding AG
SIX:ROG
188.1B CHF
32%
CH
Novartis AG
SIX:NOVN
182.7B CHF
28%
US
Pfizer Inc
NYSE:PFE
161.7B USD
19%
Ocular Therapeutix Inc
NASDAQ:OCUL
Country US
Market Cap 973.1m USD
Operating Margin
-153%
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Eli Lilly and Co
NYSE:LLY
Country US
Market Cap 744.3B USD
Operating Margin
32%
Novo Nordisk A/S
CSE:NOVO B
Country DK
Market Cap 4.1T DKK
Operating Margin
45%
Dechra Pharmaceuticals PLC
LSE:DPH
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Johnson & Johnson
NYSE:JNJ
Country US
Market Cap 364.1B USD
Operating Margin
28%
Merck & Co Inc
NYSE:MRK
Country US
Market Cap 331.8B USD
Operating Margin
10%
AstraZeneca PLC
LSE:AZN
Country UK
Market Cap 189.2B GBP
Operating Margin
18%
Roche Holding AG
SIX:ROG
Country CH
Market Cap 188.1B CHF
Operating Margin
32%
Novartis AG
SIX:NOVN
Country CH
Market Cap 182.7B CHF
Operating Margin
28%
Pfizer Inc
NYSE:PFE
Country US
Market Cap 161.7B USD
Operating Margin
19%

Profitability Report

View the profitability report to see the full profitability analysis for Ocular Therapeutix Inc.

Full Profitability Report

See Also

Summary
OCUL intrinsic value, competitors valuation, and company profile.
DCF Valuation
OCUL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OCUL stock valuation using valuation multiples.
Wall Street Estimates
OCUL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OCUL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-152.8%
=
Operating Profit
-91.4m
/
Revenue
59.8m
What is the Operating Margin of Ocular Therapeutix Inc?

Based on Ocular Therapeutix Inc's most recent financial statements, the company has Operating Margin of -152.8%.

ALPHA SPREAD
Join more than 139,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.